Vildagliptin BID

Phase 3Small molecule

Merck & Co.

Vildagliptin BID is one of 63 small molecule programs targeting Type 2 Diabetes Mellitus. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Type 2 Diabetes MellitusActive, not recruiting

Type 2 DiabetesActive, not recruiting

Type 2 Diabetes MellitusPhase 1

Active, not recruiting

Type 2 DiabetesPhase 3

Active, not recruiting

Competition

Competitive Landscape

885 competitors in Type 2 Diabetes

#DrugCompanyPhaseTrials

Byetta

AstraZeneca

Preclinical

55 2

Jardiance

Boehringer Ingelheim

Preclinical

31 3

Vildagliptin BID

Merck & Co.

Phase 3

1 4

NOVOLIN R

Novo Nordisk

Preclinical

5 5

Glargine

Eli Lilly

Preclinical

8 6

Inspra

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

2 7

Aurlumyn

BBTG International Inc.

Preclinical

1 8

Nexium

DDexcel Pharma Technologies Ltd.

Preclinical

1 9

Inderal

WWyeth-Lederle Vaccines

Preclinical

1 10

Pravachol

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

N/ANot yet recruiting

Parkinson's Disease

NCT06951334

Clinical

Trials by Indication[1]

Parkinson's Disease1 trial

Clinical Trial of Vildagliptin in Early Parkinson's Disease

Not yet recruiting·FFirst Affiliated Hospital, Sun Yat-Sen University·N/A·NCT06951334·66 enrolled

Type 2 Diabetes1 trial

Efficacy of add-on Therapy With Vildagliptin in Chinese Patients With Type 2 Diabetes Inadequately Controlled With Prior Metformin Monotherapy

Completed· Novartis logo

Novartis·Phase 3·NCT00822211·404 enrolled

Type 2 Diabetes Mellitus1 trial

A Study Comparing the Pharmacokinetic and Pharmacodynamic Profiles for Sitagliptin, Saxagliptin and Vildagliptin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-142)

Completed· Merck & Co. logo

Merck & Co.·Phase 1·NCT01582308·22 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Vildagliptin BID. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Vildagliptin BID compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Vildagliptin BID. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Merck & Co. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Merck & Co.

Vildagliptin BID

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Parkinson's Disease1 trial

Type 2 Diabetes1 trial

Type 2 Diabetes Mellitus1 trial

References

Drug Info

Quick Facts

Related News